Diabetes drug takes on statins in battle against fatty liver
NCT ID NCT07180745
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. 400 obese, diabetic adults with NAFLD/NASH will take one of five drug combinations daily for 3 months. Researchers will measure liver fat and stiffness using a special ultrasound (FibroScan) and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin, Atorvastatin, Pioglitazone
What this could lead to
If successful, this could show that empagliflozin, alone or with statins, is a better option than statins alone for reducing liver fat and stiffness in people with NAFLD/NASH.
What could go wrong
This is a Phase 4 trial, so the drugs are already approved, but it's still early for this specific use. The 3-month treatment period is short, and results may not show lasting benefits or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Teaching hospital of Beni Suef University
Banī Suwayf, 62727, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••